Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

London High Court rules in favour of NHS in Servier drug dispute

The judgement is a key milestone in the 11-year case between the French pharmaceutical company and the secretary of state for health and social care and the wider NHS

- PMLiVE

Eli Lilly launches the Institute for Genetic Medicine and a $700m facility investment

The US state-of-the-art facility will further the development of RNA and DNA-based treatments

Strictly personal: how to deliver 360-degree engagement to support your organisation’s agility and impact

By Simon Grime

New syndicated patient report – Living with Lupus US

Living with Lupus US is a new syndicated patient report which offers valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.

Inizio

- PMLiVE

England to end COVID-19 isolation laws and mass free testing

From 24 February, all COVID-19 restrictions will end in England and from 1 April, all free mass testing will finish

- PMLiVE

COVID-19 booster to be made available to those over 75 and high risk adults and children

Around 7.2 million people living in the UK aged over 75 – having already had their primary course of COVID-19 vaccines – will be eligible for the booster

- PMLiVE

Enhertu trial results show significant improvement for breast cancer patients

The treatment, jointly developed by AstraZenca and Daiichi Sankyo, was trialled in the pivotal DESTINY-Breast04 study

Biomarin

FDA keeps BioMarin’s gene therapy for phenylketonuria on hold

The decision follows data suggesting BioMarin’s experimental gene therapies may have the potential to progress cancers

EU flag

Global Blood Therapeutics’ treatment for patients with sickle cell disease approved in Europe

The once-daily oral drug is the first medicine approved in Europe to treat the condition in adults and paediatric patients 12 years and older

- PMLiVE

Sandoz launches generic oncology treatment in Europe

Lenalidomide can be used to treat patients with haemato-onocology conditions, following recommendations from recent European Society for Medical Oncology (ESMO) guidelines

Launching Health Tech Innovations in the New Normal

Aahuti Rai (Strategic Advisor, Healthcare Innovation at Four Points Consulting) & Jessica Smith (Co-Founder and CXO at SomX) discuss all things HealthTech, including the current barriers to HealthTech commercialization, holistic...

Impetus Digital

- PMLiVE

Gilead shares results from HIV trial for lenacapavir

The results were presented at the 29th Conference on Retroviruses and Opportunistic Infections – virtual CROI 2022

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links